📊 MDXG Key Takeaways
Is Mimedx Group, Inc.. (MDXG) a Good Investment?
MiMedx exhibits strong top-line growth (20% YoY) and excellent gross margins (70.6%), but the company is unprofitable with -$16.0M operating income and -$10.9M net loss, indicating severe operational inefficiency. While the balance sheet is fortress-like with $159.8M cash and minimal debt (0.07x D/E), negative free cash flow of -$108K suggests the business model is structurally unviable at current cost levels, risking cash depletion despite strong financial position.
Why Buy Mimedx Group, Inc.. Stock? MDXG Key Strengths
- Revenue growth of 20% YoY demonstrates market traction and demand
- Exceptional gross margin of 70.6% shows strong pricing power and production efficiency
- Fortress balance sheet: $159.8M cash, 5.39x current ratio, 0.07x debt-to-equity ratio provides significant runway for operational turnaround
MDXG Stock Risks: Mimedx Group, Inc.. Investment Risks
- Operating losses of -$16.0M (operating margin -27.2%) despite positive gross profit indicate bloated operating expenses and poor cost management
- Negative free cash flow (-$108K) on $59M revenue means business is unprofitable and unsustainable; cash depletion is inevitable without profitability improvement
- Negative ROE (-4.5%) and ROA (-3.5%) demonstrate capital is not generating returns; growth strategy is destroying shareholder value
Key Metrics to Watch
- Operating margin trajectory—must trend toward positive to validate turnaround thesis
- Free cash flow breakeven—critical inflection point; sustained negative FCF is death spiral indicator
- Cash burn rate and cash runway—calculate monthly burn; at current rate, determine months until depletion without additional action
Mimedx Group, Inc.. (MDXG) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.39x current ratio provides a solid financial cushion.
MDXG Profit Margin, ROE & Profitability Analysis
MDXG vs Healthcare Sector: How Mimedx Group, Inc.. Compares
How Mimedx Group, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Mimedx Group, Inc.. Stock Overvalued? MDXG Valuation Analysis 2026
Based on fundamental analysis, Mimedx Group, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Mimedx Group, Inc.. Balance Sheet: MDXG Debt, Cash & Liquidity
MDXG Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Mimedx Group, Inc..'s revenue has grown significantly by 40% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.37 reflects profitable operations.
MDXG Revenue Growth, EPS Growth & YoY Performance
MDXG Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $59.0M | $7.0M | $0.05 |
| Q3 2025 | $84.1M | $8.1M | $0.05 |
| Q2 2025 | $87.2M | $9.6M | $0.06 |
| Q1 2025 | $84.7M | $7.0M | $0.05 |
| Q3 2024 | $81.7M | $4.8M | $0.00 |
| Q2 2024 | $81.3M | $1.2M | $0.01 |
| Q1 2024 | $71.7M | -$5.0M | $-0.06 |
| Q3 2023 | $67.7M | $4.8M | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Mimedx Group, Inc.. Dividends, Buybacks & Capital Allocation
MDXG SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Mimedx Group, Inc.. (CIK: 0001376339)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MDXG
What is the AI rating for MDXG?
Mimedx Group, Inc.. (MDXG) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MDXG's key strengths?
Claude: Revenue growth of 20% YoY demonstrates market traction and demand. Exceptional gross margin of 70.6% shows strong pricing power and production efficiency.
What are the risks of investing in MDXG?
Claude: Operating losses of -$16.0M (operating margin -27.2%) despite positive gross profit indicate bloated operating expenses and poor cost management. Negative free cash flow (-$108K) on $59M revenue means business is unprofitable and unsustainable; cash depletion is inevitable without profitability improvement.
What is MDXG's revenue and growth?
Mimedx Group, Inc.. reported revenue of $59.0M.
Does MDXG pay dividends?
Mimedx Group, Inc.. does not currently pay dividends.
Where can I find MDXG SEC filings?
Official SEC filings for Mimedx Group, Inc.. (CIK: 0001376339) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MDXG's EPS?
Mimedx Group, Inc.. has a diluted EPS of $-0.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MDXG a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Mimedx Group, Inc.. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MDXG stock overvalued or undervalued?
Valuation metrics for MDXG: ROE of -4.5% (sector avg: 15%), net margin of -18.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MDXG stock in 2026?
Our dual AI analysis gives Mimedx Group, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MDXG's free cash flow?
Mimedx Group, Inc..'s operating cash flow is $1.9M, with capital expenditures of $2.0M. FCF margin is -0.2%.
How does MDXG compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -18.4% (avg: 12%), ROE -4.5% (avg: 15%), current ratio 5.39 (avg: 2).